breast cancer - adjuvant 14 studies trastuzumab emtasine plus endocrine therapy everolimus abemaciclib plus endocrine therapy palbociclib plus endocrine therapy doxorubicin plus cyclophosphamide followed by docetaxel plus trastuzumab docetaxel plus carboplatin with trastuzumab followed by trastuzumab lapatinib pertuzumab plus trastuzumab olaparib palbociclib trastuzumab emtansine pembrolizumab alone neratinib
breast cancer - HER2-positive 37 studies
es-BC - HER2 negative - (neo)adjuvant (NA) 1 studies pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamide
es-BC - HER2 positive - (neo)adjuvant (NA) 6 studies trastuzumab emtansine trastuzumab emtasine plus endocrine therapy lapatinib trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel
la/mBC - HER2 positive 30 studies
la/mBC - HER2 positive - (neo)adjuvant (NA) 3 studies lapatinib plus trastuzumab plus paclitaxel trastuzumab plus chemotherapy lapatinib plus paclitaxel
la/mBC - HER2 positive - 1st Line (L1) 7 studies trastuzumab plus endocrine therapy pertuzumab plus trastuzumab pertuzumab plus trastuzumab plus docetaxel bevacizumab plus trastuzumab plus docetaxel trastuzumab
la/mBC - HER2 positive - 2nd Line (L2) 17 studies abemaciclib plus trastuzumab lapatinib plus capecitabine afatinib plus vinorelbine neratinib plus capecitabine lapatinib plus trastuzumab tucatinib plus trastuzumab plus capecitabine inetetamab plus vinorelbine margetuximab plus chemotherapy trastuzumab emtansine trastuzumab deruxtecan abemaciclib plus trastuzumab plus fulvestrant neratinib lapatinib
breast cancer - HR positive 44 studies
es-BC - HR positive - (neo)adjuvant (NA) 2 studies trastuzumab emtansine trastuzumab emtasine plus endocrine therapy
es-BC - HR-positive - 1st line (L1) 1 studies taselisib plus letrozole
la/mBC - HR positive 41 studies
la/mBC - HR positive - (neo)adjuvant (NA) 3 studies
la/mBC - HR positive - NA - PIK3CA mutant
la/mBC - HR-positive - 1st line (L1) 14 studies
la/mBC - HR positive - L1 - PIK3CA mutant 1 studies ipatasertib plus paclitaxel
la/mBC - HR-positive - 2nd line (L2) 22 studies
la/mBC - HR positive - L2 - all population 1 studies buparlisib plus fulvestrant
la/mBC - HR positive - L2 - PIK3CA mutant 1 studies buparlisib plus fulvestrant
breast cancer - triple negative 29 studies
es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA) 6 studies
es-BC - TNBC - NA - all population 5 studies olaparib atezolizumab plus carboplatin plus nab-paclitaxel atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide pembrolizumab alone durvalumab alone
es-BC - TNBC - NA - PDL1 positive 1 studies atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide
es-BC - Triple negatif (TNBC) - 1st line (L1)
mBC - Triple negative (TNBC) - (neo)adjuvant (NA)
mBC - Triple negative (TNBC) - 1st Line (L1) 13 studies
mBC - TNBC - L1 - all population 8 studies paclitaxel plus carboplatin veliparib plus paclitaxel plus carboplatin ipatasertib plus paclitaxel capivasertib plus paclitaxel pembrolizumab plus SoC atezolizumab plus paclitaxel atezolizumab plus nab-paclitaxel
mBC - TNBC - L1 - PDL1 positive 4 studies atezolizumab plus paclitaxel pembrolizumab plus SoC atezolizumab plus nab-paclitaxel
mBC-Triple negative (TNBC) - 2nd Line (L2) 10 studies
mBC - TNBC - L2 - all population 5 studies pembrolizumab alone olaparib
mBC - TNBC - L2 - PDL1 positive 2 studies pembrolizumab alone
metastatic/advanced - breast cancer (mBC) 1 studies trastuzumab deruxtecan